LYLin Yang

Lin Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lin Yang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Ding

    Homologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China

    1 shared publication
  • Liquan Zhou

    Homologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China

    1 shared publication
  • Tianjin Ma

    Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy Hunan University of Chinese Medicine Changsha China

    1 shared publication
  • Xiao Liu

    Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy Hunan University of Chinese Medicine Changsha China

    1 shared publication
  • Yimiao Zhou

    Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy Hunan University of Chinese Medicine Changsha China

    1 shared publication
  • Zuowei Xiao

    Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China

    1 shared publication

Latest Publications

  • Open Access

    Structural Characterization and Hypoglycemic Effects of a Purified Polysaccharide From Cinnamomum cassia

    by Liquan Zhou, Yimiao Zhou, Chen Ding, Lin Yang, Tianjin Ma, Xiao Liu, Zuowei Xiao

    A purified polysaccharide, designated CCP1A, was extracted and isolated from Cinnamomum cassia bark using ultrasonic‐assisted composite enzymatic extraction followed by DEAE‐52 and Sephadex G‐100 column chromatography. CCP1A had a molecular weight of 8.161 kDa and was primarily composed of glucose and galacturonic acid, with minor amounts of rhamnose, arabinose, galactose, xylose, and mannose. Spectroscopic analyses (FT‐IR and 1 H NMR) confirmed the coexistence of α‐ and β‐glycosidic linkages and a pyranose ring structure. The Congo red assay indicated a stable helical conformation, and transmission electron microscopy revealed dendritic, coiled aggregates. In a mouse model of type 2 diabetes induced by a high‐fat diet combined with low‐dose streptozotocin, oral administration of CCP1A (100, 200, and 300 mg/kg/day for 4 weeks) dose‐dependently reduced fasting blood glucose, improved glucose tolerance and lipid profiles (TG, TC, LDL‐C, and HDL‐C), and alleviated polydipsia, polyphagia, weight loss, as well as pancreatic pathological damage. Mechanistically, CCP1A suppressed intestinal α‐amylase and α‐glucosidase activities, promoted hepatic and muscle glycogen synthesis, upregulated the hepatic mRNA expression of GCK, GLUT2, PI3K, AKT, and Nrf2, downregulated PEPCK mRNA expression, increased serum levels of T‐SOD, GSH‐Px, CAT, and T‐AOC, and decreased MDA and GSP levels. These findings suggest that CCP1A exerts multi‐target hypoglycemic effects potentially involving inhibition of intestinal glucose absorption, modulation of insulin signaling‐related genes, promotion of glycogen synthesis, suppression of gluconeogenesis, and upregulation of Nrf2 mRNA. Hence, CCP1A represents a promising natural candidate for functional food development against type 2 diabetes.